Evidence map›Paper›PMID 37267316›Full record

ArticlePloS one2023

Protein production from HEK293 cell line-derived stable pools with high protein quality and quantity to support discovery research.

Hong Sun, Songyu Wang, Mei Lu, Christine E Tinberg, Benjamin M Alba

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. TiOBioprocess and biosystems engineering · 2026
    Article
  6. Review
  7. Integrated Modular Workflows for Membrane Protein Production in HEK293 Cells.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  8. Article
  9. Highly efficient production of HIV-1Journal of virology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hong SunBiologic Therapeutic Discovery, Amgen Research, South San Francisco, California, United States of America.
Songyu WangBiologic Therapeutic Discovery, Amgen Research, South San Francisco, California, United States of America.ORCID 0000-0001-5745-436X
Mei LuBiologic Therapeutic Discovery, Amgen Research, South San Francisco, California, United States of America.
Christine E TinbergBiologic Therapeutic Discovery, Amgen Research, South San Francisco, California, United States of America.ORCID 0000-0002-6179-0435
Benjamin M AlbaBiologic Therapeutic Discovery, Amgen Research, South San Francisco, California, United States of America.
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-based therapeutics and recombinant protein reagents are often produced in mammalian expression systems, which provide human-like post-translational modifications. Among the available mammalian cell lines used for recombinant protein expression, Chinese hamster ovary (CHO)-derived suspension cells are generally utilized because they are easy to culture and tend to produce proteins in high yield. However, some proteins purified from CHO cell overexpression suffer from clipping and display undesired non-human post translational modifications (PTMs). In addition, CHO cell lines are often not suitable for producing proteins with many glycosylation motifs for structural biology studies, as N-linked glycosylation of proteins poses challenges for structure determination by X-ray crystallography. Hence, alternative and complementary cell lines are required to address these issues. Here, we present a robust method for expressing proteins in human embryonic kidney 293 (HEK293)-derived stable pools, leading to recombinant protein products with much less clipped species compared to those expressed in CHO cells and with higher yield compared to those expressed in transiently-transfected HEK293 cells. Importantly, the stable pool generation protocol is also applicable to HEK293S GnTI- (N-acetylglucosaminyltransferase I-negative) and Expi293F GnTI- suspension cells, facilitating production of high yields of proteins with less complex glycans for use in structural biology projects. Compared to HEK293S GnTI- stable pools, Expi293F GnTI- stable pools consistently produce proteins with similar or higher expression levels. HEK293-derived stable pools can lead to a significant cost reduction and greatly promote the production of high-quality proteins for diverse research projects.

Indexed as

KidneyAnimalsCHO CellsCricetinaeCricetulusHEK293 CellsHumansRecombinant ProteinsRecombinant Proteins

Identifiers

PMID37267316
PMCPMC10237474
OpenAlexW4379184144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.